Literature DB >> 7704612

Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra.

G Bing1, Y Zhang, Y Watanabe, B S McEwen, E A Stone.   

Abstract

The observation that Parkinson's disease (PD) is associated with locus coeruleus (LC) noradrenergic neuronal degeneration suggests that the LC noradrenergic system may be involved in the pathogenesis and natural progression of the destruction of the substantia nigra (SN) dopaminergic neurons in Parkinson's disease. The relationship of these two systems was examined by injection of subtoxic doses of MPTP into unilateral LC 6-hydroxydopamine (6-OHDA) lesioned mice. A significant loss of dopaminergic cells was only found in the SN on the side of the LC lesions. These results suggest that the LC may have protective effects on SN dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7704612     DOI: 10.1016/0006-8993(94)90534-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  28 in total

1.  Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats.

Authors:  C Marin; E Aguilar; M Bonastre
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

2.  Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Olivia Groover; Yoland Smith
Journal:  Neurobiol Dis       Date:  2016-12-30       Impact factor: 5.996

3.  Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.

Authors:  Mahmoud M Iravani; Mona Sadeghian; Sarah Rose; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2014-04-30       Impact factor: 3.575

4.  Norepinephrine upregulates the expression of tyrosine hydroxylase and protects dopaminegic neurons against 6-hydrodopamine toxicity.

Authors:  Meng-Yang Zhu; Muhammad U Raza; Yanqiang Zhan; Yan Fan
Journal:  Neurochem Int       Date:  2019-09-17       Impact factor: 3.921

Review 5.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

Review 6.  Noradrenergic Modulation on Dopaminergic Neurons.

Authors:  Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2018-03-23       Impact factor: 3.911

7.  Calcium channel blockers and beta-blockers in relation to Parkinson's disease.

Authors:  Thanh G N Ton; Susan R Heckbert; W T Longstreth; Mary Anne Rossing; Walter A Kukull; Gary M Franklin; Phillip D Swanson; Terri Smith-Weller; Harvey Checkoway
Journal:  Parkinsonism Relat Disord       Date:  2006-10-19       Impact factor: 4.891

8.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

9.  Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.

Authors:  V Pérez; C Marin; A Rubio; E Aguilar; M Barbanoj; J Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2009-08-27       Impact factor: 3.575

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.